↓ Skip to main content

Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma

Overview of attention for article published in Clinical Cancer Research, July 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

policy
1 policy source
twitter
5 tweeters

Citations

dimensions_citation
121 Dimensions

Readers on

mendeley
60 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma
Published in
Clinical Cancer Research, July 2016
DOI 10.1158/1078-0432.ccr-15-2825
Pubmed ID
Authors

Anne-Ségolène Cottereau, Hélène Lanic, Sylvain Mareschal, Michel Meignan, Pierre Vera, Hervé Tilly, Fabrice Jardin, Stéphanie Becker

Abstract

The prognostic impact of total metabolic tumor volume (TMTV) measured on pretreatment 18F-FDG PET/CT and its added value to molecular characteristics was investigated in patients with diffuse large B-cell lymphoma (DLBCL). For 81 newly diagnosed DLBCL patients, treated with Rituximab and CHOP/CHOP-like regimen, TMTV was computed using the 41% SUVmax thresholding method. According to the gene expression profile, determined using DASL (cDNA-mediated Annealing, Selection, Ligation and extension) technology, a subset of 57 patients was classified in GCB or ABC subtypes and MYC or BCL2 overexpressed. Median follow-up was 64 months. 5y-PFS and OS were 60% and 63% in the whole population. Median pre-therapy TMTV was 320 cm3 (25th-75th percentiles 106-668 cm3). With a 300cm3cut off, patients with high TMTV (n=43) had a 5 y-PFS and OS of 43% and 46% compared with 76% and 78% for patients with a low TMTV (p=0.0023, p=0.0047). ABC status, MYC or BCL2 overexpression and both overexpression ("dual expressor", DE) were significantly associated with a worse PFS and OS. TMTV combined with molecular data allowed a significant better risk sub-stratification of ABC/GCB patients, on PFS and OS. High TMTV individualized in molecular low risk patients a group with a poor outcome (MYC, PFS=51%, OS=55% BCL2, PFS=49%, OS=49% or DE PFS=50%, OS=50%) and a group with a good outcome (MYC, PFS=93%, OS=93% BCL2, PFS=86%, OS=86% or DE PFS=81%, OS=81%). The combination of molecular and imaging characteristics at diagnosis could lead to a more accurate selection of patients, in order to increase tailor therapy.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Unknown 59 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 22%
Student > Ph. D. Student 10 17%
Student > Master 7 12%
Student > Doctoral Student 5 8%
Other 5 8%
Other 7 12%
Unknown 13 22%
Readers by discipline Count As %
Medicine and Dentistry 34 57%
Computer Science 3 5%
Engineering 2 3%
Nursing and Health Professions 1 2%
Agricultural and Biological Sciences 1 2%
Other 4 7%
Unknown 15 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2022.
All research outputs
#5,334,523
of 21,454,959 outputs
Outputs from Clinical Cancer Research
#5,103
of 12,206 outputs
Outputs of similar age
#73,536
of 279,547 outputs
Outputs of similar age from Clinical Cancer Research
#54
of 161 outputs
Altmetric has tracked 21,454,959 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,206 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,547 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 161 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.